Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).

Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA.

J Card Fail. 2005 May;11(4):260-9.

PMID:
15880334
2.

Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure.

Goldsmith SR.

Am J Cardiol. 2005 May 2;95(9A):14B-23B. Review.

PMID:
15847853
3.

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.

Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators.

JAMA. 2004 Apr 28;291(16):1963-71.

PMID:
15113814
4.

Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure.

Chen HH, Redfield MM, Nordstrom LJ, Horton DP, Burnett JC Jr.

J Card Fail. 2004 Apr;10(2):115-9.

PMID:
15101022
5.

Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model.

Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV.

JAMA. 2003 Nov 19;290(19):2581-7.

PMID:
14625335
6.

[A simple colorimetric method of inulin determination in renal clearance studies on metabolically normal subjects and diabetics].

FUHR J, KACZMARCZYK J, KRUTTGEN CD.

Klin Wochenschr. 1955 Aug 1;33(29-30):729-30. German. No abstract available.

PMID:
13264515
7.

Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).

Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E; Studies of Left Ventricular Dysfunction.

J Am Coll Cardiol. 2003 Aug 20;42(4):705-8.

8.

Tubuloglomerular feedback and the control of glomerular filtration rate.

Vallon V.

News Physiol Sci. 2003 Aug;18:169-74. Review.

9.

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.

Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C; Tolvaptan Investigators.

Circulation. 2003 Jun 3;107(21):2690-6. Epub 2003 May 12.

10.

Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure.

Chen HH, Redfield MM, Nordstrom LJ, Cataliotti A, Burnett JC Jr.

Am J Physiol Renal Physiol. 2003 May;284(5):F1115-9.

11.

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators.

N Engl J Med. 2003 Apr 3;348(14):1309-21. Epub 2003 Mar 31. Erratum in: N Engl J Med. 2003 May 29;348(22):2271.

12.

Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial.

Russell SD, Selaru P, Pyne DA, Ghazzi MM, Massey KD, Pressler M, Serikoff A, Coats AJ.

Am Heart J. 2003 Jan;145(1):179-86.

PMID:
12514672
13.

BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy.

Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT.

Circulation. 2002 Mar 19;105(11):1348-53. Erratum in: Circulation 2002 Sep 24;106(13):1743.

14.

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.

Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, Ghali JK, Selaru P, Chanoine F, Pressler ML, Konstam MA.

Circulation. 2001 Nov 13;104(20):2417-23.

15.

Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone.

Abdallah JG, Schrier RW, Edelstein C, Jennings SD, Wyse B, Ellison DH.

J Am Soc Nephrol. 2001 Jul;12(7):1335-41.

16.

Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor.

Nakamura Y, Haneda T, Osaki J, Miyata S, Kikuchi K.

Eur J Pharmacol. 2000 Mar 10;391(1-2):39-48.

PMID:
10720633
17.

The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.

Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW.

J Am Coll Cardiol. 2000 Mar 1;35(3):681-9.

18.

Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects.

Burnier M, Fricker AF, Hayoz D, Nussberger J, Brunner HR.

Eur J Clin Pharmacol. 1999 Nov;55(9):633-7.

PMID:
10638391
19.

Mammalian distal tubule: physiology, pathophysiology, and molecular anatomy.

Reilly RF, Ellison DH.

Physiol Rev. 2000 Jan;80(1):277-313. Review.

20.

Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction.

Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ.

Circulation. 1999 Sep 21;100(12):1311-5.

Supplemental Content

Support Center